Views & Analysis | Perspectives on pharma industry issues

Oncology

pharmaphorum podcast Episode 282 at ESMO26: Dr Chuck Link, Syncromune

ESMO26: Lowering toxicity, extending lives, with Syncromune

As the ESMO26 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast.

Oncology

Why precision biomarkers will change the future of breast ca...

Blood-based biomarkers can provide an earlier, dynamic view of what is happening inside a patient, creating an opportunity to detect changes sooner.

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Oncology

Sponsored

12 Questions with Julia Jakl

Learn more about Julia Jakl, VP and Business Unit Head, Oncology UK at GSK, in a new 12 Questions With.

Market Access

Sponsored

The pre-commercial case for connecting data before acquiring...

For EBPs, launch requires a data strategy that starts with agreement on the KPIs, and those depend on the therapeutic areas.

Articles

Challenges with real-world evidence to support HTA

Tarang Sharma, expert in health economics and HTA, speaks with pharmaphorum on the challenges associated with using real-world evidence in HTA decision making. The emerging need for real-world evidence in HTA decision making is becoming apparent as regulators seek reassurance that...

Articles

Celebrating 30 years of the Orphan Drug Act and NORD

Peter L. Saltonstall shares the progress of rare disease patient advocate NORD over the last 30 years, including the introduction of the Orphan Drug Act. The year 2013 marks a dual anniversary of great significance to the rare disease community: on January 4, 1983, President...

Articles

How I became part of the Quantified Self movement

Jim Dayton shares his personal views on the increase in keeping track of one’s own health data, known as the Quantified Self movement, by using medical devices and mhealth apps. I am part of the Quantified Self movement. Which means: I am a person who believes that tracking one’s own...

Sales & Marketing

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Sales & Marketing

Building a social presence inside regulatory guardrails

In the UK, promoting prescription-only medicines to the public is prohibited by law and by the ABPI Code - social media reactions and shares included.

Digital

Sponsored

Why AI transformation is really about people

Jeff Kaminski, global head of AI and data at Axtria and a former industry analyst, discusses culture, governance, and leadership challenges around AI.

Digital